Polyrizon Ltd. Appoints New VP of Regulatory Affairs
Ticker: PLRZ · Form: 6-K · Filed: Dec 13, 2024 · CIK: 1893645
| Field | Detail |
|---|---|
| Company | Polyrizon Ltd. (PLRZ) |
| Form Type | 6-K |
| Filed Date | Dec 13, 2024 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: personnel-appointment, regulatory-affairs, pharmaceutical
TL;DR
Polyrizon beefs up regulatory team with new VP appointment.
AI Summary
Polyrizon Ltd. announced on December 13, 2024, the appointment of a new Vice President of Regulatory Affairs and Quality Assurance. This appointment is detailed in a press release attached to their Form 6-K filing.
Why It Matters
This appointment is crucial for a pharmaceutical company as it strengthens their leadership in ensuring product compliance and quality, which directly impacts market access and patient safety.
Risk Assessment
Risk Level: low — The filing is a routine announcement of a personnel appointment and does not contain significant financial or operational news.
Key Players & Entities
- Polyrizon Ltd. (company) — Registrant
- December 13, 2024 (date) — Press Release Date
- 972-54-7979668 (phone_number) — Business Phone
- 001-42375 (other) — Commission File Number
FAQ
What is the primary purpose of this Form 6-K filing?
The primary purpose of this Form 6-K filing is to report a press release issued by Polyrizon Ltd. on December 13, 2024, announcing the appointment of a new VP of Regulatory Affairs and Quality Assurance.
When was the press release attached to this filing issued?
The press release attached to this filing was issued on December 13, 2024.
What is Polyrizon Ltd.'s principal executive office address?
Polyrizon Ltd.'s principal executive offices are located at 5 Ha-Tidhar Street, Raanana, 4366507, Israel.
Does Polyrizon Ltd. file annual reports under Form 20-F or 40-F?
Polyrizon Ltd. files annual reports under Form 20-F.
What is the SIC code for Polyrizon Ltd.?
The Standard Industrial Classification (SIC) code for Polyrizon Ltd. is 2834, which corresponds to Pharmaceutical Preparations.
Filing Stats: 184 words · 1 min read · ~1 pages · Grade level 13.5 · Accepted 2024-12-13 16:00:10
Filing Documents
- ea0224740-6k_polyrizon.htm (6-K) — 9KB
- ea022474002ex99-1_polyrizon.htm (EX-99.1) — 9KB
- 0001213900-24-108853.txt ( ) — 20KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Polyrizon Ltd. Date: December 13, 2024 By: /s/ Tomer Izraeli Name: Tomer Izraeli Title: Chief Executive Officer 2